IP Verse

Novel Antitumoral Use Of Cabazitaxel

Patent No. EP2493466 (titled "Novel Antitumoral Use Of Cabazitaxel") was filed by Aventis Pharma on Oct 27, 2010. The application was issued on Mar 10, 2021.

Patent Summary

UPC Cases New

Latest UPC cases involving this patent.

Case NumberFiling DatePlaintiffProceeding Type
UPC_COA_0000027/2026Feb 12, 2026Sanofi Mature, ZentivaAppeal
UPC_COA_0000026/2026Feb 12, 2026Sanofi MatureAppeal
UPC_COA_0000025/2026Feb 12, 2026Sanofi, Sanofi AventisAppeal
UPC_COA_0000024/2026Feb 12, 2026Sanofi, Sanofi AventisAppeal
UPC_COA_0000023/2026Feb 12, 2026Sanofi, Sanofi AventisAppeal
UPC_COA_0000022/2026Feb 12, 2026Sanofi, Sanofi AventisAppeal
UPC_CFI_0000108/2026Jan 12, 2026Stada Arzneimittel, Stada NordicOther
UPC_CFI_0000106/2026Jan 12, 2026Sanofi, Sanofi AventisOther
UPC_CFI_0000099/2026Jan 12, 2026Zentiva, Zentiva FranceOther
UPC_CFI_0000098/2026Jan 12, 2026Sanofi, Sanofi AventisOther

Patent Family

Patent Family

Patent Oppositions (15)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ACCORD HEALTHCARE SLUAug 30, 2024AERA
ACCORD HEALTHCARE SLUAug 30, 2024BARDEHLE PAGENBERG SL
MAIWALDDec 10, 2021MAIWALD
STADA ARZNEIMITTELDec 9, 2021HAMM & WITTKOPP
VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBDec 3, 2021VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBB
GENERICS UKJun 8, 2021ELKINGTON AND FIFE
DR REDDYS LABORATORIES BETAPHARM ARZNEIMITTELMar 31, 2021MAIWALD
FRESENIUS KABI DEUTSCHLANDMar 23, 2021FRESENIUS KABI DEUTSCHLAND
MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATEMar 22, 2021UEXKULL & STOLBERG
ZENTIVA KSMar 12, 2021GREINER
EVER VALINJECTMar 12, 2021SONN PATENTANWALTE
ACCORD HEALTHCAREMar 10, 2021AERA
ACCORD HEALTHCAREMar 10, 2021BARDEHLE PAGENBERG SL
GLENMARK PHARMACEUTICALS EUROPEMar 10, 2021BRAND MURRAY FULLER
TEVA PHARMACEUTICALSMar 10, 2021KRAUS & LEDERER PARTGMBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2493466

AVENTIS PHARMA
Application Number
EP10782039A
Filing Date
Oct 27, 2010
Status
Opposition Rejected
Sep 19, 2025
Publication Date
Mar 10, 2021
External Links
Slate, Register , Google Patents